Cardiotoxicity of cancer chemotherapy: Implications for children

被引：134

作者：

Simbre II V.C. ^{[1
,2
]}

Duffy S.A. ^{[1
,3
]}

Dadlani G.H. ^{[1
,2
]}

Miller T.L. ^{[2
,3
]}

Lipshultz S.E. ^{[1
,2
,3
,4
]}

机构：

[1] Division of Pediatric Cardiology, University of Rochester Medical Center, Golisano Children's Hospital at Strong, Rochester, NY

[2] Department of Pediatrics, University of Rochester, School of Medicine and Dentistry, Rochester, NY

[3] Department of Pediatrics, University of Miami Miller School of Medicine, Holtz Children's Hospital, Miami, FL

[4] Department of Pediatrics, University of Miami Miller School of Medicine, Medical Campus MCCD-D820, Miami, FL 33136

来源：

Pediatric Drugs | 2005年 / 7卷 / 3期

基金：

美国国家卫生研究院;

关键词：

Paclitaxel; Doxorubicin; Cardiac Troponin; Idarubicin; Amifostine;

D O I：

10.2165/00148581-200507030-00005

中图分类号：

学科分类号：

摘要：

Many children and adolescents with cancer receive chemotherapeutic agents that are cardiotoxic. Thus, while survival rates in this population have improved for some cancers, many survivors may experience acute or chronic cardiovascular complications that can impair their quality of life years after treatment. In addition, cardiac complications of treatment lead to reductions in dose and duration of chemotherapy regimens, potentially compromising clinical efficacy. Anthracyclines are well known for their cardiotoxicity, and alkylating agents, such as cyclophosphamide, ifosfamide, cisplatin, busulfan, and mitomycin, have also been associated with cardiotoxicity. Other agents with cardiac effects include vinca alkaloids, fluorouracil, cytarabine, amsacrine, and asparaginase and the newer agents, paclitaxel, trastuzumab, etoposide, and teniposide. The heart is relatively vulnerable to oxidative injuries from oxygen radicals generated by chemotherapy. The cardiac effects of these drugs include asymptomatic electrocardiographic abnormalities, blood pressure changes, arrhythmias, myocarditis, pericarditis, cardiac tamponade, acute myocardial infarction, cardiac failure, shock, and long-term cardiomyopathy. These effects may occur during or immediately after treatment or may not be apparent until months or years after treatment. Mild myocardiocyte injury from chemotherapy may be of more concern in children than in adults because of the need for subsequent cardiac growth to match somatic growth and because survival is longer in children. Primary prevention is therefore important. Patients should be educated about the cardiotoxic risks of treatment and the need for long-term cardiac monitoring before chemotherapy is begun. Cardiotoxicity may be prevented by screening for risk factors, monitoring for signs and symptoms during chemotherapy, and continuing follow-up that may include electrocardiographic and echocardiographic studies, angiography, and measurements of biochemical markers of myocardial injury. Secondary prevention should aim to minimize progression of left ventricular dysfunction to overt heart failure. Approaches include altering the dose, schedule, or approach to drug delivery; using analogs or new formulations with fewer or milder cardiotoxic effects; using cardioprotectants and agents that reduce oxidative stress during chemotherapy; correcting for metabolic derangements caused by chemotherapy that can potentiate the cardiotoxic effects of the drug; and cardiac monitoring during and after cancer therapy. Avoiding additional cardiotoxic regimens is also important in managing these patients. Treating the adverse cardiac effects of chemotherapy will usually be dependent on symptoms or will depend on the anticipated cardiovascular effects of each regimen. Treatments include diuresis, afterload reduction, β-adrenoceptor antagonists, and improving myocardial contractility. © 2005 Adis Data Information BV. All rights reserved.

引用

页码：187 / 202

页数：15

共 155 条

[31]

Lipshultz S.E., Sallan S.E., Dalton V., Et al., Elevated serum cardiac troponin T as a marker for active cardiac injury during therapy for childhood acute lymphoblastic leukemia, J Am Coll Cardiol, 37, (2001)

[32]

Billingham M.E., Mason J.W., Bristow M.R., Et al., Anthracycline cardiomyopathy monitored by morphological changes, Cancer Treat Rep, 62, pp. 865-872, (1978)

[33]

Isner J.M., Ferrans V.J., Cohen S.R., Et al., Clinical and morphologic cardiac findings after anthracycline chemotherapy, Am J Cardiol, 51, pp. 1167-1174, (1983)

[34]

Druck M.N., Gulenchyn K.Y., Evans W.K., Et al., Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity, Cancer, 53, pp. 1667-1674, (1998)

[35]

Von Hoff D.D., Layard M.W., Basa P., Et al., Risk factors for doxorubicin-induced congestive heart failure, Ann Intern Med, 91, pp. 710-717, (1979)

[36]

Legha S.S., Benjamin R.S., Mackay B., Et al., Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous-infusion, Ann Intern Med, 96, 2, pp. 133-139, (1982)

[37]

Torti F.M., Bristow M.R., Howes A.E., Et al., Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: Assessment by endomyocardial biopsy, Ann Intern Med, 99, 6, pp. 745-749, (1983)

[38]

Weiss A.J., Metter G.E., Fletcher W.S., Et al., Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity, Cancer Treat Rep, 60, 7, pp. 813-822, (1976)

[39]

Weiss A.J., Manthel R.W., Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule with particular reference to lack of cardiac toxicity, Cancer, 40, pp. 2046-2052, (1977)

[40]

Chelobowski R.T., Paroly W.S., Pugh R.P., Et al., Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity, Cancer Treat Rep, 6, pp. 447-451, (1980)

← 1 2 3 4 5 6 7 8 9 10 →